First-in-human phase I study of PF-06747775, a third-generation mutant selective EGFR tyrosine kinase inhibitor (TKI) in metastatic EGFR mutant NSCLC after progression on a first-line EGFR TKI

Autor: Renato Martins, Peggy Senico, Wendy Ma, Mark A. Socinski, Joanna C. Masters, D-W. Kim, Nuzhat Pathan, Zelanna Goldberg, Byoung Chul Cho, Hatim Husain, Sarah B. Goldberg

Publikováno v: Annals of Oncology. 28:v485-v486

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e4611413659a71ef75563bfef6e3bb04
https://doi.org/10.1093/annonc/mdx380.060

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Autor: Hutson TE; Thomas E. Hutson, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX; Bernard Escudier, Institut Gustave Roussy, Villejuif, France; Emilio Esteban, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain; Georg A. Bjarnason, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Ho Yeong Lim, Samsung Medical Center, Seoul, Korea; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville South, Adelaide, Australia; Peggy Senico, Pfizer, Collegeville, PA; Andreas Niethammer and Dongrui Ray Lu Pfizer, La Jolla, CA; Subramanian Hariharan, Pfizer; and Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, New York, NY., Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 Mar 10; Vol. 32 (8), pp. 760-7. Date of Electronic Publication: 2013 Dec 02.